![]() |
|
|
Vol. 287, Issue 3, 854-859, December 1998
Digestive System Research Unit (S.V., A.G.-L., M.A., J.V., F.G.,
J.R.M.) and
Department of Microbiology (E.C.),
Hospital General Vall
d'Hebron, Department of Pathology (G.G., A.S.), Barcelona, Spain
Inhibition of tumor necrosis fact (TNF
) is of potential benefit in
the treatment of chronic inflammatory conditions. However, TNF
plays
an important role in host defenses against infection, and blocking
TNF
production may also have adverse effects. We tested the efficacy
and safety of anti-TNF
therapy in experimental colitis induced by
trinitrobenzenesulfonic acid. We cultured colonic wall specimens for
bacterial growth and measured native TNF
protein synthesis in
colonic tissue at days 0, 1, 4, 10 and 18 after induction of colitis.
Anti-TNF
therapy (monoclonal g1 immunoglobulin, 15 mg/kg i.p., every
third day) was started on either day 4 or day 10 after induction of
colitis. On day 18, we measured the release of inflammatory mediators
and scored colonic lesions. In acute lesions, several species of the
common flora were grown, including Streptococcus, Staphylococcus,
Bacteroides, clostridia and enterobacteria. In chronic lesions,
only enterobacteria, clostridia and lactobacilli were isolated. TNF
production by inflamed colonic tissue was increased in both acute and
chronic lesions. Anti-TNF
therapy induced a significant decrease in
the release of inflammatory mediators and histopathological remission
when treatment started on day 10. However, anti-TNF
therapy
increased eicosanoid release and lesion scores when treatment started
on day 4. In conclusion, acute colonic lesions showed polymicrobial
infection. Anti-TNF
therapy induced remission of chronic intestinal
inflammation, but early treatment did not prove effective.
This article has been cited by other articles:
![]() |
C. Medina, A. Santana, M. C. Paz, F. Diaz-Gonzalez, E. Farre, A. Salas, M. W. Radomski, and E. Quintero Matrix metalloproteinase-9 modulates intestinal injury in rats with transmural colitis J. Leukoc. Biol., May 1, 2006; 79(5): 954 - 962. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Videla, J. Vilaseca, C. Medina, M. Mourelle, F. Guarner, A. Salas, and J.-R. Malagelada Selective Inhibition of Phosphodiesterase-4 Ameliorates Chronic Colitis and Prevents Intestinal Fibrosis J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 940 - 945. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Myers, S. Murthy, A. Flanigan, D. R. Witchell, M. Butler, S. Murray, A. Siwkowski, D. Goodfellow, K. Madsen, and B. Baker Antisense Oligonucleotide Blockade of Tumor Necrosis Factor-alpha in Two Murine Models of Colitis J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 411 - 424. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Boismenu, Y Chen, K Chou, A El-Sheikh, and R Buelow Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis Ann Rheum Dis, November 1, 2002; 61(90002): ii19 - 24. [Abstract] [Full Text] [PDF] |
||||